The novel IIa HDAC inhibitor TMP195 has been shown to be effective in the treatment of breast cancer, mainly through a new strategy that induces the recruitment and differentiation of highly phagocytic and stimulatory macrophages within tumors 21. Here, HDAC9 is linked to breast carcinoma.